French call Abivax Covid-19 Phase 2b/3 miR-AGE trial Research National Priority

 

 
*Abivax's Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National 
Priority by the French government's Clinical Trial Council* 
 
  · _Research National Priority has priority for patient enrollment in clinical 
  trials for an accelerated review and approval process with the French regulatory 
  authorities_ 
 
  · _Effective Covid-19 treatments very much needed because optimal vaccination 
  coverage of millions of individuals and public acceptance will take time_ 
 
  · _ABX464 mechanism of action not expected to be impacted by viral mutations_ 
 
  · _Pivotal phase 2b/3 Covid-19 trial results expected in Q2 2021 and ABX464 
  manufacturing scale-up is ongoing to meet potential demand from commercialization 
  in 2021_ 

https://www.marketscreener.com/quote/stock/ABIVAX-22387984/news/PRESS-RELEASE-Abivax-s-Covid-19-Phase-2b-3-miR-AGE-trial-with-ABX464-declared-Research-National-Pr-32070964/